BMRN实时信号 | 通过Getagraph.com最大化利润

购买 6392 min ago

@ $83.11

发出时间: 2 May 2024 @ 03:32

回报率: -0.80%

上一信号: May 1 - 03:32

上一信号: 出售

回报率: 2.70 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	1.63M
平均成交量	1.58M
市值	15.65B
EPS	$0 ( 2024-04-24 )
下一个收益日期	( $0.570 ) 2024-07-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	77.77
ATR14	$2.27 (2.76%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-12	Bienaime Jean Jacques	Buy	20 000	Common Stock
2024-04-11	Bienaime Jean Jacques	Sell	20 000	Common Stock
2024-04-12	Bienaime Jean Jacques	Sell	20 000	Common Stock
2024-04-11	Bienaime Jean Jacques	Sell	20 000	Stock Option (Right to Buy Common Stock)
2024-04-12	Bienaime Jean Jacques	Sell	20 000	Stock Option (Right to Buy Common Stock)

INSIDER POWER
25.83
Last 93 transactions
Buy: 972 265 \| Sell: 563 201

音量相关性

長: -0.79 (moderate negative)

短: -0.97 (very strong negative)

Signal:(29) Possible Trading Opportunity Present (swing)

Biomarin Pharmaceutical 相关性

10 最正相关
MMAC	0.923
RMRM	0.916
FREQ	0.89
ABST	0.889
IMPL	0.889
TTOO	0.887
SGBX	0.887
INFI	0.885
SBBP	0.884
CFV	0.884

10 最负相关
APOP	-0.956
ICON	-0.907
RDUS	-0.893
MIND	-0.88
TRMD	-0.879
WRLD	-0.878
SYKE	-0.875
BNIXU	-0.873
SOUN	-0.873
MGTX	-0.873

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Biomarin Pharmaceutical 相关性 - 货币/商品

0.22
( neutral )

-0.17
( neutral )

0.00
( neutral )

0.74
( moderate )

-0.87
( strong negative )

Biomarin Pharmaceutical 财务报表

Annual	2023
营收:	$2.42B
毛利润:	$1.84B (76.15 %)
EPS:	$0.890

FY	2023
营收:	$2.42B
毛利润:	$1.84B (76.15 %)
EPS:	$0.890

FY	2022
营收:	$2.10B
毛利润:	$1.61B (76.92 %)
EPS:	$0.760

FY	2021
营收:	$1.85B
毛利润:	$1.38B (74.52 %)
EPS:	$-0.354

Financial Reports:

No articles found.

Biomarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.